Recent Press Releases

Celsion Corporation Announces $1 Million NIH, NIBIB - Career Development Award Grant for Glioblastoma Research with ThermoDox® and HIFU

LAWRENCEVILLE, N.J., July 21, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that its ongoing collaboration with Dr. Costas...

Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C

PLANTATION, Fla., July 22, 2014 /PRNewswire/ -- Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the Icahn School...

New technique uses 'simulated' human heart to screen drugs

A Coventry University scientist has developed a pioneering new way – using samples of beating heart tissue – to test the effect of drugs on the heart without using human or animal trials....

Potential new therapy with brain-on-a-chip axonal strain injury model

Researchers from the Biomedical Engineering Department of Rutgers, The State University of New Jersey recently demonstrated the use of their "Brain-on-a-Chip" microsystem to assess specific...

Study Links Enzyme to Alzheimer's Disease

Newswise — Unclogging the body's protein disposal system may improve memory in patients with Alzheimer's disease (AD), according to a study from scientists at Kyungpook National...

Transplanting gene into injured hearts creates biological pacemakers

LOS ANGELES – Cardiologists at the Cedars-Sinai Heart Institute have developed a minimally invasive gene transplant procedure that changes unspecialized heart cells into "biological...

New hope for treatment of Alzheimer's disease

Montreal, July 15 2014 - Judes Poirier, PhD, C.Q., from the Douglas Mental Health Institute and McGill University in Montréal (Canada) and his team have discovered that a relatively frequent...

WISCONSIN SCIENTISTS FIND GENETIC RECIPE TO TURN STEM CELLS TO BLOOD

MADISON - The ability to reliably and safely make in the laboratory all of the different types of cells in human blood is one key step closer to reality. Writing today (July 14, 2014) in the journal...

ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model

Anavex Life Sciences Corp. ("Anavex" or the "Company") (otcqb:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease,...

New Compound Treats Both Blindness and Diabetes in Animal Studies

In a new study led by UC San Francisco (UCSF) scientists, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats...

HD Biosciences and Marshall University Reach Drug Discovery Co-development Agreement

SHANGHAI, July 10, 2014 /PRNewswire/ -- HD Biosciences Co., Ltd. (HDB), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine...

Domainex Reports Success of its Lead Compound in Pre-clinical Model of COPD and Secures £1.4m Biomedical Catalyst Award

CAMBRIDGE, UK I July 9, 2014 I Domainex Ltd, a UK-based drug discovery company developing first-in-class small-molecule inhibitors of two closely-related pro-inflammatory kinases - TBK1 and...

Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction

GENEVA, Jul 10, 2014 (GLOBE NEWSWIRE via COMTEX) -- Addex Therapeutics (six:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today positive...

New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice

INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the...

Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection

Milestone Achieved under $9.4 Million NIAID Cooperative Grant Princeton, NJ – July 9, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical...

NIH funds next step of cutting-edge research into Alzheimer's disease genome

Teams of scientists will use support from the National Institutes of Health to conduct research into the genetic underpinnings of Alzheimer's disease, analyzing how genome sequences—the...

New Reprogramming Method Makes Better Stem Cells

Newswise — A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University (OHSU) and Salk Institute for Biological Studies has...

Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates

SAN DIEGO, July 1, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain,...

Blocking cells' movement to stop the spread of cancer

Insights into how cells move through the body could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours, according to new UCL research. Scientists...

Schizophrenia-Associated Gene Variation Affects Brain Cell Development

Johns Hopkins researchers have begun to connect the dots between a schizophrenia-linked genetic variation and its effect on the developing brain. As they report July 3 in the journal Cell Stem Cell,...